Drucker D J, DeForest L, Brubaker P L
Department of Medicine, Banting and Best Diabetes Centre, Toronto Hospital, University of Toronto, Ontario, Canada.
Am J Physiol. 1997 Dec;273(6):G1252-62. doi: 10.1152/ajpgi.1997.273.6.G1252.
The control of intestinal epithelial growth is regulated by interactions of growth factors in various cellular compartments of the small and large bowel. Little information is available on the intestinal growth response to combinations of growth factors. We studied the intestinotrophic properties of a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analog, human [Gly2]GLP-2 (h[Gly2]GLP-2), as well as of epidermal growth factor (EGF), long [Arg3]insulin-like growth factor I (LR3IGF-I), [Gly1]IGF-II, and human growth hormone (hGH), administered by subcutaneous injection alone or in combination in mice. At the doses tested, h[Gly2]GLP-2 was the most potent agent for increasing small and large bowel mass. Mice treated with h[Gly2]GLP-2 and either GH or IGF-I exhibited greater increases in histological parameters of small intestinal growth than did mice treated with h[Gly2]GLP-2 alone. Administration of all five growth factors together induced significant increases in crypt plus villus height and in small and large bowel length and weight. The results of these experiments define regional differences in both the cellular targets and relative activities of intestinotrophic molecules and raise the possibility that selective growth factor combinations may be useful for enhancement of intestinal adaptation in vivo.
小肠和大肠不同细胞区室中的生长因子相互作用调节肠道上皮生长。关于生长因子组合对肠道生长反应的信息很少。我们研究了二肽基肽酶IV抗性胰高血糖素样肽2(GLP-2)类似物人[Gly2]GLP-2(h[Gly2]GLP-2)以及表皮生长因子(EGF)、长效[Arg3]胰岛素样生长因子I(LR3IGF-I)、[Gly1]IGF-II和人生长激素(hGH)单独或联合皮下注射对小鼠的肠营养特性。在所测试的剂量下,h[Gly2]GLP-2是增加小肠和大肠质量最有效的药物。用h[Gly2]GLP-2与生长激素或胰岛素样生长因子I治疗的小鼠,其小肠生长的组织学参数增加幅度大于单独用h[Gly2]GLP-2治疗的小鼠。同时给予所有五种生长因子可显著增加隐窝加绒毛高度以及小肠和大肠的长度和重量。这些实验结果确定了肠营养分子在细胞靶点和相对活性方面的区域差异,并提出了选择性生长因子组合可能有助于增强体内肠道适应性的可能性。